about
Microbiological problems and biofilms associated with Mycobacterium chimaera in heater-cooler units used for cardiopulmonary bypass.Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination.Evidence for Community Transmission of Community-Associated but Not Health-Care-Associated Methicillin-Resistant Staphylococcus Aureus Strains Linked to Social and Material Deprivation: Spatial Analysis of Cross-sectional DataMapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UKPoint-of-Care Testing for Clostridium Difficile Infection: A Real-World Feasibility Study of a Rapid Molecular Test in Two Hospital Settings.Performance of the GeneXpert CT/NG assay compared to that of the Aptima AC2 assay for detection of rectal Chlamydia trachomatis and Neisseria gonorrhoeae by use of residual Aptima SamplesPerformance of a Novel Point-of-Care Molecular Assay for Detection of Influenza A and B Viruses and Respiratory Syncytial Virus (Enigma MiniLab) in Children with Acute Respiratory Infection.The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluationsAn early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in EnglandSurface-attached cells, biofilms and biocide susceptibility: implications for hospital cleaning and disinfection.Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.Contamination of the Hospital Environment From Potential Clostridium difficile Excretors Without Active Infection.Point-of-care tests for infectious diseases: barriers to implementation across three London teaching hospitals.The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy.Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach.Comparison of Control of Clostridium difficile Infection in Six English Hospitals Using Whole-Genome Sequencing.Expanding the armamentarium for the treatment of Clostridium difficile infection.Efficacy and acceptability of rectal and perineal sampling for identifying gastrointestinal colonization with extended spectrum β-lactamase Enterobacteriaceae.Universal hospital admission screening for carbapenemase-producing organisms in a low-prevalence setting.Molecular detection of common intestinal parasites: a performance evaluation of the BD Max™ Enteric Parasite Panel.Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line.Hidden burden of undiagnosed Clostridium difficile infection.A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients.The Enigma ML FluAB-RSV assay: a fully automated molecular test for the rapid detection of influenza A, B and respiratory syncytial viruses in respiratory specimens.Performance evaluation of the Verigene® (Nanosphere) and FilmArray® (BioFire®) molecular assays for identification of causative organisms in bacterial bloodstream infections.Recent emergence of carbapenem-resistant organisms in a low prevalence UK setting in London.Multiplex molecular testing for management of infectious gastroenteritis in a hospital setting: a comparative diagnostic and clinical utility study.Glutamate dehydrogenase for laboratory diagnosis of Clostridium difficile infection.Laboratory diagnosis of Clostridium difficile infection.Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile.Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents.Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review.Potential of real-time PCR threshold cycle (CT) to predict presence of free toxin and clinically relevant C. difficile infection (CDI) in patients with cancer: A reply.Faecal microbiota transplantation for recurrent Clostridium difficile infection and beyond: risks and regulation.Mandatory reporting and improvements in diagnosing Clostridium difficile infection: an incompatible dichotomy?Successful faecal microbiota transplant for recurrent Clostridium difficile infection delivered by colonoscopy through a diverted ileostomy in a patient with severe perianal Crohn's disease.Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward.Rapid detection of sequence variation in Clostridium difficile genes using LATE-PCR with multiple mismatch-tolerant hybridization probes.
P50
Q30234390-F54CEC8C-735A-4775-804A-261E29E5830CQ30381743-02E9DA32-4903-4C83-8BDC-3DFF6AECDC08Q31039977-CE8EB8C8-74B4-45D5-9B9E-A5586DBBDC62Q33996140-65417BD0-090F-473B-9107-9FE274B1F25FQ34726271-60C835C6-1A1B-4D53-9A39-5854B750A60EQ36414075-EE9F3A1F-2B8D-4A2B-AA2F-C83D353284A6Q36434424-483DFD9E-D75E-49A1-AFFE-08A7796ABF06Q36494422-201611F6-2423-4AC1-A334-7B34C3EDC624Q37599522-04974CE5-C6DD-4C6D-9A65-8107DFD83484Q38275130-FF2680DE-D0FF-4BCE-9E1C-198E5CE3F5C8Q38910301-E89B3A89-787D-49EE-995A-D5BC26E6B8FFQ38910305-C80F4A86-BF45-4537-A232-426DC1B1F9AAQ38927086-CB4BE67D-73FE-42AC-AAF5-0F544E30A379Q39302972-22942761-FFF0-47E9-A7CF-168ADF246B33Q39551108-3C395BD5-D062-40CE-94C7-9F7659F26D48Q40187460-90FF78BC-6D99-481F-9E85-39FBC571F3B6Q40230741-5657DF06-8D3C-4568-A94B-3DA49AA467B7Q40315612-C75AC1EE-EB31-488A-AAA3-100AD076D719Q40578460-0E3E1B78-8FEA-4705-A6B0-4EA4E5BFC6E0Q40619948-0995C303-71D6-4787-B2A4-E334E66900A6Q41356203-8738A936-97A5-43A3-8608-D80D4B603D89Q41629632-7EEAD184-C310-435D-8AB1-7D6E8D5D726EQ41633677-45E04D50-08DC-459F-A687-E21FE1B8A74BQ41659897-4867B17F-00B5-4E9D-AA1C-3E7910D85710Q41703078-D91EAC55-3379-4B53-9DF7-3CEC5B77BF18Q41988963-C4669E93-7E67-41C1-8123-8A4F0B501E03Q42239332-24AE1D96-9625-482C-8454-FBFDE414D56FQ42575113-5BAE9F3D-3454-4259-8CC5-5519A0B237BFQ42575311-049D526C-542B-4334-AD7E-43C6541CE01CQ43245457-D2B0B9AB-D87F-4DE9-9D3F-6BBAA8DA39EAQ45331186-2B005E48-E9EE-41B8-830F-88314AF3A0D1Q48550364-1E471A3F-9EA5-405E-8471-DFE4FB35AF3AQ49610079-9CE63CAA-0434-43DC-8ED2-C0E9215DFDC8Q49947171-7D6E1949-8C25-4933-A76C-F77095D506AAQ50033949-E1C6D6E9-4DA8-403F-A544-B7EFC9EEAEF8Q50239083-43FA6DD4-6948-4F60-B75C-D280F18779BCQ51585423-31372982-DAEE-4334-A5BE-96BB1AA5EABCQ52673321-B313A4DC-62EA-4C05-A683-9757BBBF6DE9Q54225792-4CD8C884-B403-41E7-9935-95F1BFA7C84DQ54292004-8D8599B3-A4BB-4B8F-9AF6-07998634F9B3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Simon D. Goldenberg
@ast
Simon D. Goldenberg
@en
Simon D. Goldenberg
@es
Simon D. Goldenberg
@sl
type
label
Simon D. Goldenberg
@ast
Simon D. Goldenberg
@en
Simon D. Goldenberg
@es
Simon D. Goldenberg
@sl
prefLabel
Simon D. Goldenberg
@ast
Simon D. Goldenberg
@en
Simon D. Goldenberg
@es
Simon D. Goldenberg
@sl
P106
P1153
14119824600
P21
P31
P496
0000-0003-0837-7382